StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) company profile

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.82+0.05 (+0.74%)

Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –

About Arvinas

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biotechnology business that develops targeted therapies using a proprietary proteolysis targeting chimera protein degradation platform. Its technology directs the body's natural protein disposal mechanisms to break down and remove disease-causing proteins. Operating across oncology and neurology therapeutic areas, the company's clinical pipeline includes vepdegestrant for advanced breast cancer, ARV-102 for neurodegenerative disorders, ARV-806 for solid tumors, ARV-393 for non-Hodgkin lymphoma, and ARV-027. The firm also maintains research collaborations with pharmaceutical partners such as Pfizer and Genentech. Its target end-users are patients suffering from severe oncologic and neurological conditions.

The provided text does not state the location of the company's headquarters. Regarding operational scale, seven drug programs generated from its discovery platform have advanced into clinical trials, alongside several preclinical candidates and research programs. In terms of geographic reach, the text references regulatory submissions and clinical activities in the United States, as well as clinical trial application clearance in the Netherlands.

Summary of the business section of Arvinas's latest annual report, written by StockData.

Company profile

Company

Legal name
Arvinas, Inc.
Founded
2013
Headquarters
New Haven, CT
Address
395 Winchester Ave, 5 Science Park 06511
Phone
(203) 535-1456
Employees
246, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
ARVN
Exchange
Nasdaq
IPO date
Sep 27, 2018
Shares outstanding
65M, Jul 31, 2026
Public float
$469.00M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1655759
CUSIP
04335A105
ISIN
US04335A1051
FIGI
BBG00LW7YK82
Share class FIGI
BBG00LW7YL08
EIN
47-2566120

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Randy TeelPresident and CEO, Director285,009
David K. LoomisVP, Chief Accounting Officer39,961
Andrew SaikChief Financial Officer187,432
Angela M. CacaceChief Scientific Officer180,390
Noah BerkowitzChief Medical Officer191,395
Ian TaylorPresident, R&D160,785
Everett CunninghamDirector41,572
Briggs MorrisonDirector111,548
Linda BainDirector41,572
Edward Moore Kennedy Jr.Director84,290
Leslie V. NorwalkDirector41,572
Alsup Laurie SmaldoneDirector41,572
John G. HoustonDirector1,122,183
Sunil AgarwalDirector30,166
John D. YoungDirector26,045

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.53M$2.58M$2.79M$14$125
FY2024$12.75M$3.23M$3.42M$23$93
FY2023$7.63M$5.98M$2.73M$48$94
FY2022$9.55M$6.68M$3.52M$40$90
FY2021$12.60M$9.30M$4.26M$97$100
FY2020$8.02M$26.46M$2.89M$207$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
John Houston
Former President and Chief Executive Officer
$706.24K$2.69M$2.67M$457.00K$14.00K$6.53M-49%
Andrew Saik
Chief Financial Officer and Treasurer
$542.06K$1.26M$1.28M$263.50K$14.00K$3.36M-3%
Noah Berkowitz
Chief Medical Officer
$552.39K$1.37M$1.39M$268.50K$14.00K$3.59M-40%
Angela Cacace
Chief Scientific Officer
$500.76K$1.26M$1.28M$243.40K$14.00K$3.30M+11%
Ian Taylor
Former President of Research and Development
$152.57K$364.34K$362.47K–$24.02K$903.39K-79%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 27, 2018
Offer price
$16.00
Securities offered
7,500,000
Gross proceeds
$120.00M
Exchange
Nasdaq
First trading day
Sep 27, 2018
First-day close
$16.05+0.3%
Lock-up ends (est.)
Mar 26, 2019

“The initial public offering price per share is $16.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 246 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 28, 2018Name changeName changed from ARVINAS HOLDING COMPANY, LLC to ARVINAS INC.
Sep 27, 2018IPOInitial public offering priced (424B4 prospectus)
Sep 21, 2018ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?